CRNX
Price
$35.61
Change
+$1.36 (+3.97%)
Updated
Sep 5 closing price
Capitalization
3.35B
60 days until earnings call
INSM
Price
$145.10
Change
+$2.57 (+1.80%)
Updated
Sep 5 closing price
Capitalization
30.67B
45 days until earnings call
Interact to see
Advertisement

CRNX vs INSM

Header iconCRNX vs INSM Comparison
Open Charts CRNX vs INSMBanner chart's image
Crinetics Pharmaceuticals
Price$35.61
Change+$1.36 (+3.97%)
Volume$1.42M
Capitalization3.35B
Insmed
Price$145.10
Change+$2.57 (+1.80%)
Volume$2.53M
Capitalization30.67B
CRNX vs INSM Comparison Chart in %
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. INSM commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a StrongBuy and INSM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (CRNX: $35.61 vs. INSM: $145.10)
Brand notoriety: CRNX and INSM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 155% vs. INSM: 96%
Market capitalization -- CRNX: $3.35B vs. INSM: $30.67B
CRNX [@Biotechnology] is valued at $3.35B. INSM’s [@Biotechnology] market capitalization is $30.67B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileINSM’s FA Score has 1 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • INSM’s FA Score: 1 green, 4 red.
According to our system of comparison, INSM is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 5 TA indicator(s) are bullish while INSM’s TA Score has 3 bullish TA indicator(s).

  • CRNX’s TA Score: 5 bullish, 5 bearish.
  • INSM’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, CRNX is a better buy in the short-term than INSM.

Price Growth

CRNX (@Biotechnology) experienced а +14.91% price change this week, while INSM (@Biotechnology) price change was +6.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

CRNX is expected to report earnings on Nov 06, 2025.

INSM is expected to report earnings on Oct 23, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INSM($30.7B) has a higher market cap than CRNX($3.35B). INSM YTD gains are higher at: 110.168 vs. CRNX (-30.354). CRNX has higher annual earnings (EBITDA): -419.62M vs. INSM (-938.1M). INSM has more cash in the bank: 1.86B vs. CRNX (1.2B). CRNX has less debt than INSM: CRNX (49.9M) vs INSM (576M). INSM has higher revenues than CRNX: INSM (398M) vs CRNX (1.39M).
CRNXINSMCRNX / INSM
Capitalization3.35B30.7B11%
EBITDA-419.62M-938.1M45%
Gain YTD-30.354110.168-28%
P/E RatioN/AN/A-
Revenue1.39M398M0%
Total Cash1.2B1.86B64%
Total Debt49.9M576M9%
FUNDAMENTALS RATINGS
CRNX vs INSM: Fundamental Ratings
CRNX
INSM
OUTLOOK RATING
1..100
2392
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
634
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
4836
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
3950

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INSM's Valuation (77) in the Biotechnology industry is in the same range as CRNX (89) in the Pharmaceuticals Major industry. This means that INSM’s stock grew similarly to CRNX’s over the last 12 months.

INSM's Profit vs Risk Rating (4) in the Biotechnology industry is somewhat better than the same rating for CRNX (63) in the Pharmaceuticals Major industry. This means that INSM’s stock grew somewhat faster than CRNX’s over the last 12 months.

CRNX's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as INSM (99) in the Biotechnology industry. This means that CRNX’s stock grew similarly to INSM’s over the last 12 months.

INSM's Price Growth Rating (36) in the Biotechnology industry is in the same range as CRNX (48) in the Pharmaceuticals Major industry. This means that INSM’s stock grew similarly to CRNX’s over the last 12 months.

INSM's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CRNX (100) in the Pharmaceuticals Major industry. This means that INSM’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXINSM
RSI
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
72%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 6 days ago
69%
Momentum
ODDS (%)
Bullish Trend 3 days ago
74%
N/A
MACD
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 4 days ago
68%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
73%
Advances
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 6 days ago
70%
Declines
ODDS (%)
Bearish Trend 19 days ago
78%
Bearish Trend 4 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
72%
Aroon
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IIM11.850.08
+0.68%
INVESCO VALUE Municipal Income TRUST
IEUR66.830.35
+0.53%
iShares Core MSCI Europe ETF
IIGD24.930.05
+0.22%
Invesco Investment Grade Defensive ETF
XTL135.660.15
+0.11%
SPDR® S&P Telecom ETF
CPSR24.66N/A
-0.01%
Calamos S&P 500 Structured Alt Protection ETF - March

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+3.97%
XNCR - CRNX
63%
Loosely correlated
+2.15%
IDYA - CRNX
58%
Loosely correlated
+5.15%
RVMD - CRNX
58%
Loosely correlated
+3.98%
NRIX - CRNX
57%
Loosely correlated
+8.66%
SYRE - CRNX
56%
Loosely correlated
+0.06%
More

INSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INSM has been closely correlated with THAR. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then THAR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INSM
1D Price
Change %
INSM100%
+1.80%
THAR - INSM
76%
Closely correlated
-7.77%
NWPHF - INSM
49%
Loosely correlated
N/A
CARM - INSM
46%
Loosely correlated
+25.59%
ROIV - INSM
44%
Loosely correlated
+2.78%
CRNX - INSM
42%
Loosely correlated
+3.97%
More